<?xml version="1.0" encoding="UTF-8"?>
<xml>
 <records>
  <record>
   <ref-type name="Journal Article">17</ref-type>
   <contributors>
    <authors>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
     <author></author>
    </authors>
   </contributors>
   <titles>
    <title></title>
   </titles>
   <dates>
    <year>2023</year>
    <pub-dates>
     <date>2023-01-25</date>
    </pub-dates>
   </dates>
   <doi>10.1016/j.ncrna.2022.10.003</doi>
   <abstract>Introduction: Hemorrhagic fever with renal syndrome (HFRS), caused by Orthohantaviruses, occupies one of the&#13;
leading places among natural focal human diseases, for which there are no modern accurate and highly sensitive&#13;
diagnostic methods. To improve this situation, a better understanding of the Hantavirus pathogenesis of HFRS is&#13;
required. Determination of the expression level of exosomal microRNAs (miRNAs) in the serum/plasma of patients makes them potential biomarkers for diagnosing and predicting HFRS. The purpose of this study was to&#13;
analyze the expression level of miRNA-146a, miRNA-126, miRNA-218, miRNA-410, miRNA-503 and miRNA-155&#13;
in patients with HFRS at different stages (fever stage, polyuric stage and convalescence stage) and with different&#13;
severity of the course this disease&#13;
Materials and methods: The moderate group of patients with HFRS included 105 patients, the severe group&#13;
included 99 patients, and the severe group with complications included 84 patients. Blood samples from patients&#13;
with HFRS for molecular genetic analysis were collected three times: during the initial febrile period (days 1–4 of&#13;
illness), the polyuric period (days 15–22 of the disease), and during convalescence. Total RNA isolation was&#13;
performed using the exoRNeasy Midi Kit (Qiagen, Germany). Quantitative real-time PCR (qRT-PCR) was performed using the miRCURY LNA SYBR Green PCR Kit (Qiagen, Germany) and the LightCycler96 real-time PCR&#13;
product detection system (Roche, Switzerland).&#13;
Results: When comparing the expression level of exosomal miRNAs in groups of patients with different severity of&#13;
the disease, a statistically significant increase in the expression level of miRNA-146a was revealed in patients&#13;
with severe HFRS with complications (Fold change 2.694; p = 0.0022) compared to the group with a moderate&#13;
disease form, as well as an increase in miRNA-155 expression in patients with severe and severe HFRS with&#13;
complications compared to the moderate form (Fold change 1.861; p = 0.0492; Fold change 1.976; p = 0.001,&#13;
respectively). Comparative analysis of the expression level of other miRNAs in patients with HFRS at various&#13;
stages and with different severity of HFRS did not reveal any statistically significant results (P &gt; 0.05).&#13;
Conclusions: MiRNA-155 and miRNA-146a may be promising prognostic biomarkers in HFRS. However, further&#13;
investigations are needed to evaluate the changes in the expression of miRNAs and the network of genes that can&#13;
be potential targets for the studied miRNAs in order to elucidate the molecular mechanisms that can influence&#13;
the occurrence and development of HFRS</abstract>
   <urls>
    <web-urls>
     <url>https://repo.bashgmu.ru/publication/3978</url>
    </web-urls>
    <pdf-urls>
     <url>https://repo.bashgmu.ru/files/4154</url>
    </pdf-urls>
   </urls>
  </record>
 </records>
</xml>
